Vericel Stock Price, News & Analysis (NASDAQ:VCEL)

$4.60 -0.25 (-5.15 %)
(As of 12/15/2017 02:34 PM ET)
Previous Close$4.85
Today's Range$4.55 - $4.85
52-Week Range$2.25 - $6.30
Volume411,500 shs
Average Volume501,844 shs
Market Capitalization$169.30 million
P/E RatioN/A
Dividend YieldN/A
Beta3.03

About Vericel (NASDAQ:VCEL)

Vericel logoVericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311

Debt

Debt-to-Equity Ratio0.44%
Current Ratio2.50%
Quick Ratio2.22%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.38 million
Price / Sales2.95
Cash FlowN/A
Price / CashN/A
Book Value($0.43) per share
Price / Book-10.70

Profitability

Trailing EPS($0.88)
Net Income$-19,560,000.00
Net Margins-45.11%
Return on Equity-265.45%
Return on Assets-52.01%

Miscellaneous

Employees202
Outstanding Shares34,910,000

Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel Corporation (NASDAQ:VCEL) posted its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $14.26 million for the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. View Vericel's Earnings History.

When will Vericel make its next earnings announcement?

Vericel is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Vericel.

Where is Vericel's stock going? Where will Vericel's stock price be in 2017?

3 equities research analysts have issued 1 year price targets for Vericel's shares. Their predictions range from $6.00 to $7.00. On average, they anticipate Vericel's stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Vericel.

Who are some of Vericel's key competitors?

Who are Vericel's key executives?

Vericel's management team includes the folowing people:

  • Robert L Zerbe M.D., Independent Chairman of the Board (Age 66)
  • Dominick C. Colangelo, President, Chief Executive Officer, Director (Age 52)
  • Gerard J. Michel, Chief Financial Officer, Vice President - Corporate Development (Age 51)
  • Daniel R. Orlando, Chief Operating Officer, Chief Commercial Officer (Age 49)
  • Ross Tubo, Chief Scientific Officer (Age 55)
  • David Recker M.D., Chief Medical Officer (Age 58)
  • Steven C. Gilman Ph.D., Director (Age 64)
  • Heidi Hagen, Director (Age 46)
  • Kevin F. McLaughlin, Director (Age 60)
  • Paul Kevin Wotton Ph.D., Director (Age 56)

Who owns Vericel stock?

Vericel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Archon Capital Management LLC (7.50%), Stonepine Capital Management LLC (2.79%), Perkins Capital Management Inc. (1.71%), EAM Investors LLC (0.48%), JPMorgan Chase & Co. (0.17%) and Citadel Advisors LLC (0.11%). View Institutional Ownership Trends for Vericel.

Who sold Vericel stock? Who is selling Vericel stock?

Vericel's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. View Insider Buying and Selling for Vericel.

Who bought Vericel stock? Who is buying Vericel stock?

Vericel's stock was acquired by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, Perkins Capital Management Inc., EAM Investors LLC, JPMorgan Chase & Co. and Citadel Advisors LLC. View Insider Buying and Selling for Vericel.

How do I buy Vericel stock?

Shares of Vericel can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of Vericel stock can currently be purchased for approximately $4.60.

How big of a company is Vericel?

Vericel has a market capitalization of $169.30 million and generates $54.38 million in revenue each year. The biotechnology company earns $-19,560,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Vericel employs 202 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]


MarketBeat Community Rating for Vericel (VCEL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vericel (NASDAQ:VCEL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.752.75
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.33$6.33$6.33$6.00
Price Target Upside: 5.56% upside5.56% upside47.29% upside110.53% upside

Vericel (NASDAQ:VCEL) Consensus Price Target History

Price Target History for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ:VCEL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/2/2017BTIG ResearchSet Price TargetBuy$6.00LowView Rating Details
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$7.00HighView Rating Details
3/13/2017Needham & Company LLCReiterated RatingBuy -> Buy$9.00 -> $6.00HighView Rating Details
4/5/2016Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
3/12/2016Ladenburg Thalmann Financial ServicesReiterated RatingBuyN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Vericel (NASDAQ:VCEL) Earnings History and Estimates Chart

Earnings by Quarter for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ VCEL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018        
11/7/2017Q3 2017($0.17)($0.16)$14.26 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.24)($0.08)$16.95 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.19)($0.31)$9.36 millionViewN/AView Earnings Details
11/7/2016Q3($0.28)($0.38)$10.93 millionViewListenView Earnings Details
5/10/2016Q116($0.25)($0.08)$11.60 million$14.10 millionViewListenView Earnings Details
3/14/2016Q415($0.15)($0.28)$17.36 million$15.40 millionViewListenView Earnings Details
11/13/2015Q315($0.21)($0.26)$10.50 million$11.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.16)$11.31 million$13.60 millionViewListenView Earnings Details
5/14/2015Q115($0.14)($0.27)$11.10 million$10.80 millionViewListenView Earnings Details
3/23/2015Q414($0.47)($0.17)$10.70 million$14.70 millionViewListenView Earnings Details
11/13/2014Q314($0.66)($0.52)$6.73 million$9.66 millionViewN/AView Earnings Details
8/14/2014Q214($1.59)($0.94)$2.50 million$4.43 millionViewN/AView Earnings Details
5/15/2014Q114($0.92)($1.26)ViewN/AView Earnings Details
3/13/2014Q413($1.34)($0.97)$0.02 million$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($2.02)($0.06)ViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Vericel (NASDAQ:VCEL) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.6 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Vericel (NASDAQ:VCEL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vericel (NASDAQ VCEL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 33.17%
Insider Trades by Quarter for Vericel (NASDAQ:VCEL)
Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Vericel (NASDAQ VCEL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2016Consonance Capital ManagementMajor ShareholderSell120,000$5.39$646,800.00View SEC Filing  
9/16/2014Daniel OrlandoCOOBuy9,804$2.55$25,000.20View SEC Filing  
9/16/2014Dominick ColangeloCEOBuy20,000$2.55$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vericel (NASDAQ VCEL) News Headlines

Source:
DateHeadline
BRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap FinancialBRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial
www.reuters.com - December 7 at 10:57 AM
Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of CreditFacilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit
globenewswire.com - December 7 at 10:57 AM
Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel UsageVericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage
finance.yahoo.com - December 7 at 10:57 AM
How Vericel Corporation’s (VCEL) EPS Growth Stacks Up Against Industry PerformanceHow Vericel Corporation’s (VCEL) EPS Growth Stacks Up Against Industry Performance
finance.yahoo.com - December 7 at 10:57 AM
-$0.10 Earnings Per Share Expected for Vericel Corporation (VCEL) This Quarter-$0.10 Earnings Per Share Expected for Vericel Corporation (VCEL) This Quarter
www.americanbankingnews.com - December 2 at 5:28 PM
Vericel (VCEL) Lowered to "Sell" at ValuEngineVericel (VCEL) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - December 2 at 12:40 AM
Vericel to Present at 29th Annual Piper Jaffray Healthcare ConferenceVericel to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 18 at 9:59 AM
Vericel Corporation (VCEL): Time For A Financial Health CheckVericel Corporation (VCEL): Time For A Financial Health Check
finance.yahoo.com - November 18 at 9:59 AM
 Brokerages Anticipate Vericel Corporation (VCEL) to Announce -$0.13 Earnings Per Share Brokerages Anticipate Vericel Corporation (VCEL) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - November 14 at 7:58 AM
Critical Contrast: Kadmon Holdings (KDMN) & Vericel Corporation (VCEL)Critical Contrast: Kadmon Holdings (KDMN) & Vericel Corporation (VCEL)
www.americanbankingnews.com - November 13 at 5:15 AM
ETFs with exposure to Vericel Corp. : November 8, 2017ETFs with exposure to Vericel Corp. : November 8, 2017
finance.yahoo.com - November 9 at 9:23 AM
Edited Transcript of VCEL earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of VCEL earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 8:21 PM
Vericel Corporation (VCEL) Issues  Earnings ResultsVericel Corporation (VCEL) Issues Earnings Results
www.americanbankingnews.com - November 7 at 4:20 PM
Vericels (VCEL) CEO Dominick Colangelo on Q3 2017 Results - Earnings Call TranscriptVericel's (VCEL) CEO Dominick Colangelo on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 3:18 PM
Vericel Reports Third-Quarter 2017 Financial Results - GlobeNewswire (press release)Vericel Reports Third-Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 12:59 PM
Vericel Corporation to Host Earnings CallVericel Corporation to Host Earnings Call
finance.yahoo.com - November 7 at 12:59 PM
Vericel Reports Third-Quarter 2017 Financial ResultsVericel Reports Third-Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 12:59 PM
Head to Head Contrast: Novus Therapeutics (NVUS) & Vericel Corporation (VCEL)Head to Head Contrast: Novus Therapeutics (NVUS) & Vericel Corporation (VCEL)
www.americanbankingnews.com - November 6 at 11:04 PM
Vericel Corporation (VCEL) & KalVista Pharmaceuticals (KALV) Financial AnalysisVericel Corporation (VCEL) & KalVista Pharmaceuticals (KALV) Financial Analysis
www.americanbankingnews.com - October 31 at 11:10 PM
Analyzing Anika Therapeutics (ANIK) & Vericel Corporation (VCEL)Analyzing Anika Therapeutics (ANIK) & Vericel Corporation (VCEL)
www.americanbankingnews.com - October 31 at 10:00 AM
Vericel Corporation (VCEL) Scheduled to Post Quarterly Earnings on TuesdayVericel Corporation (VCEL) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:58 AM
ETFs with exposure to Vericel Corp. : October 26, 2017ETFs with exposure to Vericel Corp. : October 26, 2017
finance.yahoo.com - October 26 at 12:04 PM
Vericel to Host Third-Quarter 2017 Earnings Webcast and ... - GlobeNewswire (press release)Vericel to Host Third-Quarter 2017 Earnings Webcast and ... - GlobeNewswire (press release)
globenewswire.com - October 25 at 8:56 PM
Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
finance.yahoo.com - October 25 at 8:56 PM
Vericel Corporation (VCEL) versus Peregrine Pharmaceuticals (PPHM) Head-To-Head SurveyVericel Corporation (VCEL) versus Peregrine Pharmaceuticals (PPHM) Head-To-Head Survey
www.americanbankingnews.com - October 25 at 7:12 AM
First Week Of December 15th Options Trading For Vericel (VCEL)First Week Of December 15th Options Trading For Vericel (VCEL)
www.thestreet.com - October 24 at 11:56 AM
ETFs with exposure to Vericel Corp. : October 16, 2017ETFs with exposure to Vericel Corp. : October 16, 2017
finance.yahoo.com - October 17 at 8:42 AM
VIVUS (VVUS) vs. Vericel Corporation (VCEL) Head to Head ContrastVIVUS (VVUS) vs. Vericel Corporation (VCEL) Head to Head Contrast
www.americanbankingnews.com - October 7 at 2:22 PM
Vericel Surrenders 6 Days Of GainsVericel Surrenders 6 Days Of Gains
www.benzinga.com - October 6 at 12:22 PM
Vericel Provides Business Updates at 2017 Cell & Gene Meeting on the MesaVericel Provides Business Updates at 2017 Cell & Gene Meeting on the Mesa
finance.yahoo.com - October 6 at 12:22 PM
 Brokerages Anticipate Vericel Corporation (VCEL) Will Post Earnings of -$0.17 Per Share Brokerages Anticipate Vericel Corporation (VCEL) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - October 5 at 8:22 PM
Reviewing Vericel Corporation (VCEL) & Its CompetitorsReviewing Vericel Corporation (VCEL) & Its Competitors
www.americanbankingnews.com - October 5 at 2:14 AM
Vericel Corporation (VCEL): Risks You Need To Consider Before BuyingVericel Corporation (VCEL): Risks You Need To Consider Before Buying
finance.yahoo.com - October 4 at 8:55 AM
ETFs with exposure to Vericel Corp. : October 3, 2017ETFs with exposure to Vericel Corp. : October 3, 2017
finance.yahoo.com - October 3 at 2:26 PM
ETFs with exposure to Vericel Corp. : October 3, 2017ETFs with exposure to Vericel Corp. : October 3, 2017
finance.yahoo.com - October 3 at 2:26 PM
Vericel Corporation (VCEL) Given "Buy" Rating at BTIG ResearchVericel Corporation (VCEL) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - October 2 at 1:20 PM
Short Interest in Vericel Corporation (VCEL) Declines By 23.5%Short Interest in Vericel Corporation (VCEL) Declines By 23.5%
www.americanbankingnews.com - October 1 at 2:38 AM
Vericel Corp Higher For Fourth Day In A Row - BenzingaVericel Corp Higher For Fourth Day In A Row - Benzinga
www.benzinga.com - September 29 at 6:57 PM
Vericel to Present at the 2017 Cell & Gene Meeting on the MesaVericel to Present at the 2017 Cell & Gene Meeting on the Mesa
globenewswire.com - September 28 at 9:05 AM
Comparing Kamada (KMDA) and Vericel Corporation (VCEL)Comparing Kamada (KMDA) and Vericel Corporation (VCEL)
www.americanbankingnews.com - September 25 at 8:54 AM
Financial Survey: Fortress Biotech (FBIO) & Vericel Corporation (VCEL)Financial Survey: Fortress Biotech (FBIO) & Vericel Corporation (VCEL)
www.americanbankingnews.com - September 24 at 4:22 PM
Comparing Vericel Corporation (VCEL) and BioMarin Pharmaceutical (BMRN)Comparing Vericel Corporation (VCEL) and BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - September 24 at 4:08 AM
Vericel Corp. :VCEL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017Vericel Corp. :VCEL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 23 at 10:43 AM
ETFs with exposure to Vericel Corp. : September 22, 2017ETFs with exposure to Vericel Corp. : September 22, 2017
finance.yahoo.com - September 23 at 10:43 AM
Vericel to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceVericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 10:48 AM
Vericel Corporation (VCEL) & its Peers Financial ComparisonVericel Corporation (VCEL) & its Peers Financial Comparison
www.americanbankingnews.com - September 11 at 1:06 PM
Vericel Corporation (VCEL) Receives "Buy" Rating from BTIG ResearchVericel Corporation (VCEL) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - September 7 at 10:34 AM
Vericel Corporation (VCEL) Expected to Announce Earnings of -$0.21 Per ShareVericel Corporation (VCEL) Expected to Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - August 11 at 2:36 PM
Vericels (VCEL) CEO Nick Colangelo on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaVericel's (VCEL) CEO Nick Colangelo on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 9:19 AM
Edited Transcript of VCEL earnings conference call or presentation 9-Aug-17 12:00pm GMTEdited Transcript of VCEL earnings conference call or presentation 9-Aug-17 12:00pm GMT
finance.yahoo.com - August 10 at 9:19 AM

SEC Filings

Vericel (NASDAQ:VCEL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vericel (NASDAQ:VCEL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vericel (NASDAQ VCEL) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.